FDA Eyes Peptide Use in Compounded Drugs

The U.S. health department is implementing a temporary measure, permitting pharmacies and physicians to compound drugs utilizing a range of peptide ingredients. This interim policy remains in effect while regulatory bodies determine the formal approval status of these substances for use in compounded medicines. The decision follows a recommendation from an FDA advisory panel in July to reduce compounding restrictions on six out of seven peptides evaluated. Notably, the popular tissue-repair compound BPC-157 is among those peptides identified for potentially fewer restrictions. Peptides, which are short chains of amino acids, have seen a significant rise in popularity over the past year. This surge is largely attributed to endorsements from wellness influencers, promoting their use for a variety of applications including anti-aging, muscle recovery, and tissue repair.